目的是分析巴西至今已报道的最大一组HIV和淋巴瘤患者中生存相关因素。这项回顾性、观察性、多中心研究涉及巴西圣保罗市五个机构。筛选了2000年1月至2019年12月期间连续诊断为HIV淋巴瘤的患者病历。纳入标准包括年龄超过17岁和淋巴瘤经活检确诊。收集的数据包括年龄、性别、分期（安·阿伯制）、HIV感染持续时间、CD4+淋巴细胞计数、HIV病毒载量、乳酸脱氢酶、红细胞沉降率和血清β -2-微球蛋白水平、治疗和结果。总共有276例患者被纳入研究。中位年龄为42岁。大多数患者为男性（74.3％），具有0或1的东部合作肿瘤组织（ECOG）表现状况（分别为28.6％和46.4％）。大多数患者患有非霍奇金淋巴瘤（89.2％，n=246），尤其是弥漫大B细胞淋巴瘤（40.9％）和伯基特淋巴瘤（26.4％）。霍奇金淋巴瘤占9.4％。晚期III/IV阶段是主要的（86.8％）。诊断淋巴瘤时的HIV病毒载量在52.9％的患者中可检测到。记录了53％的患者CD4计数<200个/mm³。大多数患者（62.4％）使用联合抗逆转录病毒疗法。显著影响生存的因素是：ECOG表现状况、淋巴瘤亚型、分期、β -2-微球蛋白水平、中枢神经系统（CNS）浸润、CNS浸润位置、复发/难治性淋巴瘤和国际预后指数评分。HIV状况、CD4淋巴细胞计数和复发/难治性疾病影响生存。利妥昔单抗似乎并未改善HIV相关淋巴瘤的预后。 版权所有 ©2023 Wolters Kluwer Health，Inc。

To analyze the factors associated with survival in the largest cohort of individuals with HIV and lymphoma so far described in Brazil.A retrospective, observational, multicenter study involving five institutions in São Paulo, Brazil.The medical records of consecutive patients with HIV diagnosed with lymphoma between January 2000 and December 2019 were screened. Inclusion criteria consisted of age over 17 years and a biopsy-confirmed diagnosis of lymphoma. The data collected included age, sex, staging (Ann Arbor system), duration of HIV infection, CD4+ lymphocyte count, HIV viral load, lactate dehydrogenase, erythrocyte sedimentation rate and serum beta-2-microglobulin levels, treatment and outcome.Overall, 276 patients were included. Median age was 42 years. Most patients were male (74.3%) and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (28.6% and 46.4%, respectively). Most had non-Hodgkin lymphomas (89.2%, n = 246), particularly diffuse large B-cell lymphoma (40.9%) and Burkitt lymphoma (26.4%). Hodgkin lymphoma accounted for 9.4%. Advanced stages III/IV were predominant (86.8%). HIV viral load at the moment of lymphoma diagnosis was detectable in 52.9% of patients. A CD4 count of <200 cells/mm3 was recorded for 53% of the patients. Most patients (62.4%) were on combination antiretroviral therapy. The factors that significantly affected survival were: the ECOG performance status, lymphoma subtype, staging, beta-2-microglobulin level, central nervous system (CNS) infiltration, site of CNS infiltration, relapsed/refractory lymphoma and International Prognostic Index score.HIV status, CD4-lymphocyte count and relapsed/refractory disease affected survival. Rituximab did not appear to improve outcome in HIV-related lymphomas.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.